03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
01:18 , May 12, 2018 |  BioCentury  |  Finance

HKEX opportunity knocking

The rapid growth of biotech in the greater China region is something Jefferies does not intend to miss. With the opening of a new biotech chapter on the Hong Kong Exchanges and Clearing Ltd. on...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for...
22:36 , Feb 9, 2018 |  BioCentury  |  Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
20:45 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Chinese biotech KBP raises $76 million series A

KBP Biosciences Co. Ltd. (Jinan, China) raised a $76 million series A round on Jan. 5 co-led by Advantech Capital and SDIC Venture Capital, with participation from Sangel Capital, Ping An Ventures, Bay City Capital...
13:06 , Jan 5, 2018 |  BC Extra  |  Financial News

Chinese biotech KBP raises $76 million series A

KBP Biosciences Co. Ltd. (Jinan, China) raised a $76 million series A round co-led by Advantech Capital and SDIC Venture Capital, with participation from Sangel Capital, Ping An Ventures, Bay City Capital GF XINDE Life...
23:51 , Oct 19, 2017 |  BC Innovations  |  Finance

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey...
23:04 , Apr 26, 2017 |  BC Innovations  |  Translation in Brief

Delivering Model T CARs

A Fred Hutchinson Cancer Research Center team believes its two chimeric antigen receptor (CAR) delivery platforms could lower immunological and financial costs enough to turn engineered immune cell therapies into widely accessible treatments. With two...
00:21 , Apr 5, 2017 |  BC Week In Review  |  Clinical News

SequestOx: Clinical trial started

Elite began an open-label, crossover, pivotal clinical bioequivalence trial to compare single doses of a new formulation of SequestOx vs. its original formulation and a comparator product under fed conditions in 45 healthy volunteers. Last...